Stockreport

Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States [Yahoo! Finance]

Immix Biopharma, Inc.  (IMMX) 
PDF No change in patient enrollment timing LOS ANGELES, April 18, 2024 (GLOBE NEWSWIRE) -- Nexcella, an Immix Biopharma, Inc. subsidiary (Nasdaq: IMMX) (“ImmixBio”, “Comp [Read more]